Safety-Related Labeling Changes

Vaccination with zoster vaccine recombinant, adjuvanted is recommended for patients who are seropositive to VZV, either prior to or during MAVENCLAD treatment, including when their lymphocyte counts are less than or equal to 500 cells per microliter.

Trade Name

Mavenclad

Updated Section

4.4 Special Warnings and Special Precautions for Use

Month

Sep,2022